By Alex Kowalski
PBN Staff Writer
THOUSAND OAKS, Calif. – Amgen Inc., one of the world’s largest biotechnology companies, plans to invest $200 million on a new manufacturing facility in Singapore.
The investment, spent over the next several years, will be used to fund the construction of a “world-class” manufacturing facility in Tuas Biomedical Park (TBP), reported the company, which also has a production facility in West Greenwich.
A strategic move globally, Amgen’s foreign investment places it in a position to recruit from a local pool of industry talent from nearby colleges and universities for facility positions.
“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” Madhu Balachandran, executive vice president of operations, said in prepared remarks.
Set to begin construction within a few months, the facility’s primary function will be to expand the manufacture of monoclonal antibodies, which includes Amgen’s osteoporosis treatment Prolia, or denosumab.
TBP is Singapore’s commercial hub for biomedical giants, including GlaxoSmithKline, Lonza, Merck, Novartis, Pfizer and Roche.